Navigation Links
ARISE INFUSION THERAPY SERVICES Now Infusing Ocrevustm (Ocrelizumab) For Relapsing and Primary Progressive Forms of Multiple Sclerosis
Date:7/26/2017

Written By: Ashley D. Beall, MD, FACR

Arise Infusion is pleased to now offer a major advancement in drug therapy for patients living with relapsing and primary multiple sclerosis that can significantly improve their lives. Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy that has been proven to significantly reduce signs of disease activity and mitigate the progressive disability that individuals afflicted with this disease often experience. “This new biologic treatment provides hope for individuals that have not had any available FDA-approved therapies. We are committed to helping those who can benefit with access to this medication”, said Ashley Beall, MD, FACR, Medical Director of Arise Infusion.

OCREVUS became available to patients in the U.S. in March of this year after receiving FDA approval for the treatment of multiple sclerosis. OCREVUS is administered by intravenous infusion by a nurse and is only available at a licensed infusion center. The first dose is given as two 300 mg infusions two weeks apart. Subsequent doses are given as single 600 mg infusions every six months. Arise Infusion Therapy Services is one of the first infusion centers in the metropolitan Washington DC area to offer this treatment. Arise Infusion is committed to helping patients access this exciting new treatment by handling the pre-authorization process and helping to secure co-payment assistance for those in need.

About multiple sclerosis
Multiple sclerosis (MS) is a chronic disease for which there is currently no cure. MS affects an estimated 400,000 people in the U.S. The disease occurs when the body’s immune system attacks the insulation (myelin sheath) surrounding its own nerve cells in the brain, spinal cord and optic nerves, causing inflammation that disrupts nerve impulses. This damage can lead to a wide range of symptoms, including muscle weakness, fatigue and visual changes, and may eventually lead to disability. Most people with MS experience their first symptom between 20 and 40 years of age, making the disease the leading cause of non-traumatic disability in younger adults.  

ARISE INFUSION THERAPY SERVICES has five conveniently located centers in the Washington D.C. metropolitan area that provide safe and cost-effective infusion therapy.  Arise Infusion centers are modern and attractive with many amenities to ensure patients’ comfort.  Arise treats patients with auto-immune and inflammatory conditions who aren’t so sick that they need to be treated in a hospital and aren’t so frail that they require home care. Emphasizing a “safety first” philosophy, Arise Infusion centers are staffed with highly trained registered nurses working under physician supervision. The offices are bright, cheerful places where people come to manage their conditions so they can lead full and productive lives.

The Arise Infusion team helps to manage all issues related to insurance pre-authorization, payment arrangements, and scheduling to ensure a smooth and pleasant infusion experience.  

For more information regarding Arise Infusion visit our website at http://www.ariseinfusion.com or call 240-514-5000.

Read the full story at http://www.prweb.com/releases/2017/07/prweb14547186.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. Highly drug resistant, virulent strain of Pseudomonas aeruginosa arises in Ohio
2. RE/MAX Agent Charise Goodnight Helps Children in Need Have a Good Day
3. Promising Results Arise from Phase 2 Vaccine Study for Mesothelioma
4. Magnesium Infusion: Review Examines Ian Clark's New Pure Magnesium Product
5. InfusionPoints, LLC Achieves ISO 9001:2008 Certification
6. Medtronic Infusion Pump Recall Lawyers: Resource4thePeople Announces Free Consultations Will Be Available over the Holidays
7. Transparency Market Research Adds Report on Global Infusion System Market to its Repository
8. Asia-Pacific Market for Infusion Therapy Devices Led by Terumo, JMS and Nipro Medical is expected to reach over $900 million by 2020
9. APAC Infusion Therapy Device Market Analysed and Forecast in New iData Research Study Available at MarketPublishers.com
10. Infusion Pumps Market: An Overview of Growth Prospects and Market Restraints: Transparency Market Research
11. Global Medical Robotic Systems Market Will Be Driven By Infusion Of Technology In Medical Devices Industry From 2014 To 2020: Grand View Research, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... ... a board-certified veterinary oncologist, has agreed to serve as strategic adviser to ... Dr. Tripp is founder of the Bridge Animal Referral Center (BARC) in ...
(Date:9/19/2017)... TX (PRWEB) , ... September 19, 2017 , ... ... the United States, named Dr. Howard Ng, as the new Medical Director of its ... be the new facility Medical Director of our Pflugerville- FM 685 location,” said Dr. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Ron Norman, CEO ... today the importance of making a distinct rather than generic impression in the job ... to look through a stack of resumes knows that the first impression they give ...
(Date:9/19/2017)... ... September 19, 2017 , ... When it comes to household safety, there are ... on how to keep babies and toddlers safe, and there's no better time for ... Great Time to Check Labels, Brands that sell all kinds of common consumer products ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... app offering. The new app provides a modern design with a more streamlined ... experience. , The fred’s Pharmacy mobile app includes hundreds of digital coupons that ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
Breaking Medicine Technology: